XTL Biopharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-1.03	-1.78	-1.35	0.44	-2.95
Depreciation & Amortization	0.2	-	0	0	0
Stock-Based Compensation	0.26	0	0.01	0.04	0.05
Other Adjustments	-1.83	2.08	0.9	-2.95	4.11
Change in Receivables	0.04	-	-	-	-
Changes in Accounts Payable	0.21	0.02	-0.04	-0.02	0.02
Changes in Other Operating Activities	-0.06	0.05	0.03	-0.03	0.02
Operating Cash Flow	-1.62	-0.71	-0.9	-1.05	-0.85
Capital Expenditures	-0.05	-	-	-	-0
Purchases of Investments	-0.01	-	-	-	-
Payments for Business Acquisitions	-0.41	-	-	-	-
Other Investing Activities	-0.37	0.04	0.04	0.01	0.03
Investing Cash Flow	-0.84	0.04	0.04	0.01	0.03
Long-Term Debt Repaid	-0.01	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-0.01	-	-	-	-
Issuance of Common Stock	1.46	-	-	0.39	-
Net Common Stock Issued (Repurchased)	1.46	-	-	0.39	-
Financing Cash Flow	1.45	-	-	0.39	-
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.02	-0.03	-0.01	-0.01	-0.01
Net Cash Flow	-1.02	-0.67	-0.87	-0.66	-0.82
Free Cash Flow	-1.67	-0.71	-0.9	-1.05	-0.85
FCF Margin	-370.73%	-	-	-	-
Free Cash Flow Per Share	-0.24	-0.13	-0.17	-0.17	-0.17
Levered Free Cash Flow	-1.01	-1.72	-1.37	0.38	-2.91
Unlevered Free Cash Flow	-2.12	-0.7	-0.9	-1.08	-0.9

Updated Dec 31, 2024. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q